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Duchenne muscular dystrophy (DMD) is characterized 
by the absence of dystrophin. Several previous studies 
demonstrated the feasibility of delivering microdystro-
phin complementary DNA (cDNA) into mouse and 
 normal nonhuman primate muscles by ex vivo gene 
 therapy. However, these animal models do not repro-
duce completely the human DMD phenotype, while the 
dystrophic dog model does. To progress toward the use 
of the best animal model of DMD, a dog microdystro-
phin was transduced into human and dystrophic dog 
muscle precursor cells (MPCs) with a lentivirus before 
their transplantation into mouse muscles. One month 
following MPC transplantation, myofibers express-
ing the dog microdystrophin were observed. We also 
used another approach to introduce this transgene into 
myofibers, i.e., the electrotransfer of a plasmid coding 
for the dog microdystrophin. The plasmid was injected 
into mouse and dog muscles, and brief electric pulses 
were applied in the region of injection. Two weeks later, 
the transgene was detected in both animals. Therefore, 
ex vivo gene therapy and electrotransfer are two possible 
methods to introduce a truncated version of dystrophin 
into myofibers of animal models and eventually into 
myofibers of DMD patients.
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published online 23 February 2010. doi:10.1038/mt.2010.23
IntroductIon
Duchenne muscular dystrophy (DMD) is an X-linked genetic dis-
ease characterized by the absence of dystrophin. This large protein 
of 427 kd is encoded by a 14 kb mRNA.1 This protein, interacting 
with other membrane-associated proteins, would to be needed to 
insure mechanical stress resistance of the sarcolemma during mus-
cle contraction. The lack of dystrophin weakens the sarcolemma 
and thus makes myofibers less resistant to mechanical stress.2,3
There is currently no efficient treatment for DMD. Several 
groups have however obtained promising results with a variety 
of approaches in clinical and preclinical experiments such as 
the exon skipping4 or the use of different types of stem cells.5 
The transplantation of normal allogeneic muscle precursor cells 
(MPCs) has been proven effective to restore the expression of dys-
trophin, but requires immunosuppression to avoid rejection of the 
allogeneic cells and myofibers.6,7 Cossu’s laboratory reported good 
expression of dystrophin after intra-arterial delivery of normal 
mesoangioblasts in dystrophic dogs, but this therapeutic approach 
also needed immunosuppression because of the allogeneic con-
text of the grafts.8 The systemic delivery of mesoangioblasts seems 
very promising, but it is very important to verify the potential side 
effects of the accumulation of these cells in different vital organs. 
Two recent experiments in dogs demonstrated good expression of 
dystrophin after intramuscular, regional limb delivery approach or 
intravenous delivery with an adenovirus-associated virus (AAV) 
in dystrophic dogs but they also needed immunosuppression to 
prevent an immune reaction against the delivered vector.9,10
Immunosuppressive drugs induce several adverse effects such 
as increased risks of cancer, infections, nephrotoxicity, neuro-
toxicity, and so on. One way to eventually avoid the immune 
problems associated with allogeneic cell transplantation or viral 
vector injections is to transplant autologous cells, which have 
been genetically modified ex vivo. This technique has been proven 
effective with a truncated version of dystrophin in the mouse11 
and in the nonhuman primate models.12 However, the best ani-
mal model to study the effects of experimental therapies for DMD 
is the muscular dystrophy dog, because its dystrophic phenotype 
is closer to the DMD patient than the dystrophic mouse. Indeed, 
while research with nonhuman primates is of importance, there 
is no monkey with muscular dystrophy available for experimen-
tation. Therefore, the present study will focus on the use of the 
dog microdystrophin. A recent study showed expression of this 
truncated version of dog dystrophin into dystrophic dog mus-
cles after its intramuscular delivery with an AAV, but immuno-
suppression would be required to obtain a long-term expression. 
With this therapeutic approach there is not only a requirement 
for immunosuppression but also some potential toxicity follow-
ing the dissemination of the virus throughout the body.13 Another 
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approach to avoid these problems is to directly electrotransfer a 
 complementary DNA (cDNA) coding for the gene of interest into 
muscles. A clinical trial performed on nine DMD patients has 
shown weak expression of human dystrophin in up to 6% of the 
myofibers following intramuscular injection of a plasmid contain-
ing the full-length dystrophin gene.14 This technique was safe, fast, 
and easy to use, although it needs to be substantially improved, as 
could be the case using electrotransfer to increase the incorpora-
tion of the plasmid into more myofibers.15 Moreover, this electro-
transfer technique is already in clinical trials.16
In the present study, a lentivirus vector was used to introduce 
a dog microdystrophin cDNA into human and dystrophic dog 
MPCs. This vector was selected for its property to integrate into 
the genome and to be able to carry a microdystrophin. The geneti-
cally modified MPCs were transplanted into immunodeficient 
mouse muscles and myofibers expressing the dog microdystrophin 
were observed. Moreover, the electrotransfer of the same cDNA 
was tested with success in mouse and dog muscles. Afterwards, 
we plan to introduce the microdystrophin into dystrophic dog 
muscles with these two techniques.
results
In vitro expression of the dog microdystrophin
Since dystrophin is normally expressed in myotubes and mus-
cle fibers but not in MPCs, we have chosen to clone the dog 
microdystrophin cDNA (µDys) under the control of a muscle cre-
atine kinase (MCK) promoter in a lentiviral backbone. To track its 
expression, this transgene was fused with the V5 tag (µDysV5). 
A puromycin resistance gene was also included in the backbone 
in order to allow cell selection. This plasmid (pLeMCK.µDysV5) 
(Figure 1a) was first transduced in human MPCs (hMPCs) using 
the packaging cell supernatant. Transduced cells were selected 
with 2 days exposure to puromycin. Puromycin-resistant cells 
were proliferated to confluence and placed 3 days in differentia-
tion medium to form myotubes. Proteins were harvested from 
cells grown in proliferation and differentiation media to verify that 
the transgene was only expressed in myotubes and not in MPCs. 
A western blot with an antibody against the V5 tag was performed 
to verify whether the µDysV5 protein was expressed in these cells. 
As expected, only the cultures of transduced hMPCs in differen-
tiation medium expressed the dog microdystrophin (Figure 1b).
electrotransfer of the µdysV5 plasmid  
into mouse muscles
In the aim to introduce the µDysV5 transgene by electrotransfer in 
dog muscles, a pilot study was first made in mouse muscles. A plas-
mid coding for green fluorescent protein (pLeGFP) was initially 
injected into the tibialis anterior (TA) to determine the efficiency 
of this method. Forty microgram of pLeGFP were electrotrans-
ferred into the TAs of immunodeficient (Rag−/−) mice (n = 4). 
Two weeks later, the TAs were harvested and GFP was detected in 
cryostat sections up to 40% in the best cases (Figure 2a). After this 
proof of principle, the pLeMCK.µDysV5 (40 µg) was electrotrans-
ferred into Rag−/− mouse TAs (n = 8). Mice were sacrificed after 
2 weeks and the TAs were analyzed. Immunofluorescence with an 
antibody recognizing the V5 tag was performed revealing myo-
fibers-expressing V5, and thus the dog microdystrophin. In the 
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Figure 1 In vitro experiments with the lentivirus coding for the dog 
microdystrophin fused with a V5 tag and for the puromycin resis-
tance gene. (a) Schematic representation of the pLeMCK.µDysV5. The 
dog microdystrophin (µDys) is fused with the V5 tag and is under the 
control of the MCK promoter. The puromycin resistance gene is under 
the ubiquitous promoter SV40. (b) Western blot made with uninfected 
and infected hMPCs cultured in proliferation or in fusion media. The V5 
tag was detected only in infected cells in fusion (150 kd). hMPC, human 




Figure 2 cross-sections of mouse muscles electrotransferred with 
the pleGFP and pleMcK.µdysV5. (a) The electrotransfer of the pLe-
GFP induced the expression of GFP in several myofibers. (b) The fluo-
rescent immunodetection of V5 in a muscle electrotransferred with the 
pLeMCK.µDysV5 shows several myofibers-expressing V5 in the typical 
subsarcolemmal location of dystrophin. Bar = 50 µm. The cross-sections 
represent the global result from the electrotransfer with n = 4 for pLeGFP 
and n = 8 for pLeMCK.µDysV5. MCK, muscle creatine kinase; pLeGFP, 
plasmid coding for green fluorescent protein.
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leMcK.µdysV5-transduced hMPcs grafted  
in mouse muscles
After this first positive in vivo result, hMPCs were transduced with 
the LeMCK.µDysV5 lentivirus. Cells were selected with puro-
mycin and 106 puromycin-resistant hMPCs were transplanted in 
the TAs of Rag−/− mice (n = 8). Two days before, the TAs of these 
mice were irradiated to inhibit the proliferation of the endoge-
nous satellite cells17 and injected with 1 µg of cardiotoxin to dam-
age the muscle.18 One month after the transplantation, the TAs 
were harvested and immunohistochemical staining of V5 tag was 
used to detect the expression of the dog µDys. Roughly 30–40% 
of the myofibers expressed V5 and thus the dog microdystrophin 
(Figure 3a–c). The myofibers expressing this transgene, observed 
following the cell transplantation, were more abundant than those 
observed following electrotransfer.
Influence of donor’s age in the success of dog  
MPc transplantation in mice
Muscle biopsies from a young (3 month old) and a mature (3 years 
old) dog were taken and their MPCs isolated and proliferated 
in vitro. Preliminary experiments showed that dog myoblasts had a 
tendency to fuse at confluence as low as 50% (even in high- serum 
medium) and that their proliferation was not as good as that of 
hMPCs. The low proliferation and early fusion were even more 
important when MPCs were obtained from the older dog. Indeed, 
no myofiber expression of dog dystrophin was observed 1 month 
after transplantation of nondystrophic MPCs (n = 4) from the older 
donor in Rag−/− mouse muscles (Figure 4a) whereas transplanta-
tion of nondystrophic MPCs (n = 4) from the young donor showed 
many myofibers-expressing dog dystrophin (Figure 4b).
Immortalization and leMcK.µdysV5 transduction  
of dystrophic dog MPcs
Since, we initially had just biopsies from a 2-year-old dystrophic 
dog, its MPCs were transduced with lentivirus coding for cyclin-
dependent kinase 4 (Cdk4) and telomerase to immortalize them. 
After 2 months, several clones were obtained from these immor-
talized dog MPCs, and some were selected for their high-desmin 
expression and their capacity to fuse in vitro. Western blot against 
telomerase, Cdk4 and desmin were done to confirm the two 
transductions and the myogenic potential of the transduced cells 
(Figure 5a). The 2G4 clone was discarded because no expression of 
Cdk4 nor desmin was detected. The selected clones, 2C5, 5B7, and 
5F10, were transduced with the LeMCK.µDysV5 virus. As these 
clones already contained a puromycin resistance gene (included in 
the telomerase plasmid), puromycin selection of cells containing 
the MCK.µdysV5 transgene was not possible. In consequence, the 
modified MPCs were transferred to a differentiation medium to 
activate the MCK promoter and proteins were harvested to make a 
western blot to detect V5 (Figure 5b). The 2C5 clone expressed the 
dog microdystrophin whereas only a very weak band was observed 
in the 5B7 clone and no expression was detected for the 5F10 clone. 
Thus, the 2C5 clone expressed the MCK.µDysV5 transgene.
transplantation of leMcK.µdysV5-transduced 
dystrophic dog MPcs in mice
The three clones transduced with the LeMCK.µDysV5 virus (5 × 105 
cells each) were transplanted into the TA of Rag−/− mice (n = 4 for 
each clone) before obtaining the western blot results for V5. In this 
case, the TAs did not receive irradiation nor cardiotoxin to be closer 
to the clinical situation of cell transplantation. One month after the 
graft, the TAs were harvested and immunohistochemical staining 
for V5 was used to detect the expression of dog µDysV5 in cryostat 
sections of the grafted muscles. As expected, no V5 expression was 
a cb
Figure 3 cross-sections of mouse muscles grafted with hMPcs trans-
duced with the pleMcK.µdysV5. The sections (a–c) of three different 
mice illustrate V5 expression in several myofibers in the typical sarcolem-
mal location of dystrophin. Bar = 50 µm. The cross-sections represent the 
global result from the transplantation with n = 8. hMPC, human muscle 
precursor cell; MCK, muscle creatine kinase.
a
b
Figure 4 cross-sections of mouse muscles grafted with dog MPcs. 
An antibody that recognizes dog dystrophin but not mouse dystrophin 
was used in immunohistochemistry. The transplantation of (a) mature 
dog MPCs did not induce expression of dog dystrophin whereas many 
fibers expressed dog dystrophin after the transplantation of (b) young 
dog MPCs. Bar = 100 µm. The cross-sections represent the global result 
from the transplantation with n = 4 for each group. MPC, muscle pre-
cursor cell.
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detected in muscles grafted with the 5F10 clone (Figure 6a) nor 
with the 5B7 clone (Figure 6b). Nevertheless, some myofibers-
 expressing V5 were observed in muscles grafted with the 2C5 clone 
(Figure 6c). Thus the transplantation of transduced dystrophic dog 
MPCs with the LeMCK.µDysV5 virus allowed the expression of the 
dog microdystrophin in myofibers of the grafted muscles.
electrotransfer of the pleMcK.µdysV5  
into dog muscles
Finally, the pLeMCK.µDysV5 was electrotransferred into dog 
muscles. Two hundred microgram of this plasmid were injected in 
the brachialis anterior of three nondystrophic 2-year-old dogs. Two 
weeks after the electrotransfer, myofibers expressing the transgenic 
dog microdystrophin were observed in cryosections of the three 
dogs using an antibody against the V5 flag (Figure 7a,c), but twice 
less myofibers expressed this transgene than following electro-
transfer into mouse muscles. To verify whether µDysV5 induced 
an immune response in these animals, the muscle sections were 
stained with hematoxylin–eosin. Accumulations of mononuclear 
cells with a lymphocyte aspect were observed in the muscle sec-
tions. These lymphocyte accumulations colocalized (Figure 7c,d) 
or did not colocalized (Figure 7a,b) with myofibers-expressing V5. 
An immunohistochemical staining for CD8+ confirmed that many 
of these cells were cytotoxic T-lymphocytes (Figure 7e).
dIscussIon
In this study, we have managed to introduce a truncated version 
of the dog dystrophin with a lentiviral vector into human and dys-
trophic dog MPCs. We also obtained the expression of the dog 
microdystrophin into mouse muscles following the  transplantation 
of these genetically modified MPCs. This potential therapeutic 
approach consisting in the autotransplantation of the patient own 
cells after their genetic correction in vitro is called “ex vivo gene 
therapy”. In the case of genetic myopathies, ex vivo gene therapy 
has already shown promising results, using different techniques of 
gene modification in human, mouse, and monkey cells, grafted in 
mice and nonhuman primates.11,12,19
Our first experiment was to insert the dog microdystrophin 
cDNA into hMPCs. We begin with these cells because they are 
easy to proliferate in culture. Since dystrophin is usually only 
expressed in myotubes and muscle fibers but not in MPCs,20 we 
placed the microdystrophin cDNA under the control of a MCK 
promoter21 to obtain dystrophin expression in physiological con-
ditions. Using this promoter, the expression of the transgene fol-
lowing cell transplantation is only induced when the genetically 
modified MPCs fused with the host myofibers. Thus the expression 
of the dog microdystrophin was only detected in the myotubes 
formed in culture by transduced MPCs using western blot and in 
the  muscles grafted with these cells by immunohistochemistry.
The V5 expression following transduced hMPC transplanta-
tion was more pronounced than following the transplantation of 
transduced dystrophic dog MPCs. This may be due to the lower 
proliferating capacity of the dog MPCs compared to hMPCs. 
Moreover, MPCs isolated from a young dog had more prolifera-
tion and fusion capacities than those from a mature dog. In some 
of our experiments, the transduced MPCs came from a dystrophic 
dog that was 2 years old and had been previously transduced with 
a telomerase and a Cdk4 lentivirus to increase their proliferation 
capacity.22 Even if we selected the best cell clones, their capacity 
to proliferate and to fuse was inferior to those observed for MPCs 
derived from a 3-month-old dog. It is also probable that the dys-
trophic dog MPCs were close to senescence before or between the 
two transductions and selections. The immortalization induced 



















Figure 5 Western blots on immortalized dog MPc clones transduced 
with leMcK.µdysV5. (a) Western blots to detect telomerase, Cdk4, and 
desmin in uninfected dog MPCs (U) and four different clones infected 
with the telomerase and the Cdk4 viruses, namely 2C5, 2G4, 5B7, and 
5F10. Telomerase, Cdk4, and desmin were detected only in clones 2C5, 
5B7, and 5F10. (b) Western blot to detect V5 in the three clones selected 
for their expression of telomerase, Cdk4, and desmin, transduced with 
the LeMCK.µDysV5 virus and transferred in differentiation medium. A 
clear expression of V5 was detected (150 kd) in clone 2C5, a very weak 
expression of V5 was distinguished in the 5B7 clone and no V5 expres-
sion was noticed in the 5F10 clone. Cdk4, cyclin-dependent kinase 4; 
MPC, muscle precursor cell; MW, molecular weight.
a cb
Figure 6 cross-sections of mouse muscles transplanted with the 
three immortalized dog MPc clones infected with the leMcK.
µdysV5 virus, treated for fluorescent immunodetection of V5. No 
V5 tag was detected in muscles grafted with the (a) 5F10 and (b) 5B7 
clones. On the contrary, some myofibers expressed the V5 tag at the 
sarcolemmal position in the muscles grafted with the (c) 2C5 clone. 
Bar = 50 µm. The cross-sections represent the global results from the 
transplantation with n = 4 for each group. MCK, muscle creatine kinase; 
MPC, muscle precursor cell.
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restore the low-fusion capacity of these cells compared to the fusion 
capacity of MPCs isolated from a young dog. What is important, 
however, is that despite this potential senescence/fusion problem, 
we obtained some expression of dog microdystrophin after the 
graft of the MCK.µdysV5-transduced dystrophic dog MPCs into 
mouse muscles. For future experiments, biopsies from dystrophic 
dogs should be taken from young dogs so that their proliferation 
and fusion capacity are better.
In addition to the experiments of ex vivo gene therapy, we also 
tested with success the electrotransfer of the plasmid coding for the 
dog microdystrophin both in mouse and dog muscles. However, 
our transgene was more expressed in the mouse muscles, probably 
simply due to an easier and more effective electrotransfer tech-
nique in the small muscles (i.e., mice) than bigger muscles (i.e., 
dogs). In addition, the electric parameters for electrotransfer in 
smaller muscles are already well-established whereas this is not 
the case for large dog muscles.
This method combining the uses of electrotransfer and gene 
therapy has been used in muscles, tumors, and skin in large ani-
mals such as dogs, pigs, nonhuman primates, and is currently in 
clinical trials to treat different diseases.16,23 In particular, this tech-
nique allows a long-term expression of a plasmid in skeletal mus-
cles because muscle fibers are postmitotic. Compared to ex vivo 
gene therapy, this is a faster method because there is no cellular 
culture and this may also be less immunogenic and safer since 
viral capsids are not introduced in the patients.24 Even whether 
during the electrotransfer, some injected plasmids may reach the 
blood circulation, the use of a muscle-specific promoter will insure 
that transgene expression is restricted to myofibers. In addition, 
the incorporation of naked plasmids by myofibers, without elec-
trotransfer, is very low. Despite the lower electrotransfer efficiency 
in our experiments in comparison with the ex vivo gene therapy 
results, electrotransfer remains a potential method to introduce 
dystrophin cDNA especially in small muscles. This technique 
should be further improved in the future.
In our study, to detect the truncated dystrophin in the dogs, it 
was necessary to distinguish it from the endogenous dystrophin. 
To do so, we used a V5 tag in fusion with the protein. However, 
this tag may induce an immune response at long-term.12 In our 
electrotransfer experiment in dogs, a cellular infiltration, i.e., a 
sign of a specific immune response, was observed in the regions 
expressing the transgene at 2 weeks. In the future, we will extend 
our electrotransfer experiments in dystrophic dogs to verify 
whether the specific immune response producing the rejection of 
the myofibers is due to the microdystrophin itself or to the V5 
tag. A specific immune response may also be induced by the use 
of antibiotic-resistance genes used to select the transduced cells; 
in our case, the electrotransferred plasmid contained the µDysV5 
and the puromycin resistance gene. In fact, an autologous graft 
of dog MPCs genetically modified with a lentivirus, containing 
only this resistance gene, induced a specific immune response at 
the injection sites (data not shown). This preliminary result sug-
gests that the puromycin resistance gene can induce an immune 
response by itself.
We expect that this immune problem will be absent in future 
experiments of electrotransfer or ex vivo gene therapy in dystro-
phic dogs. For these experiments, the V5 tag and the puromy-
cin resistance gene will be removed from the plasmid because 
we will be able to detect the microdystrophin without needing 
a tag. Obviously, in this case the percentage of revertant fibers 
will have to be taken into account. However, we cannot exclude 
that an immune response against microdystrophin may appear. 
Figure 7 cross-sections of dog muscles electrotransferred with the pleMcK.µdysV5. Two regions (from two different muscles) are shown 
through serial sections respectively in a, b, and c, d, e. (a,c) Fluorescent immunodetection of V5 shows the typical sarcolemmal location of dystro-
phin in several myofibers. (b,d) The hematoxylin–eosin staining shows infiltrates of mononuclear cells with the aspect of lymphocytes (arrowheads) 
in the proximity of the V5-positive myofibers. (e) The fluorescent immunodetection of CD8+ cells shows that many cells in the mononuclear infiltrates 
are cytotoxic T-lymphocytes. The asterisks indicate the same myofibers through the sections. Bar = 150 µm (a,b) and 75 µm (c–e). The cross-sections 
represent the global results from the electrotransfer with n = 3. MCK, muscle creatine kinase.
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There were contradictory results in previous experiments in 
dystrophic mice receiving transplantation of syngeneic MPCs 
expressing normal dystrophin. One study reported the pro-
duction of antibodies reacting with dystrophin, but without 
inducing rejection at long-term.25 Another study reported both 
antibody production and specific T-lymphocyte reaction against 
dystrophin, leading to rejection.26 In DMD patients, antidystro-
phin antibodies were also observed following nondystrophic 
MPC grafts.27
Recent studies using intramuscular injection of AAV2 and 
AAV6 vectors carrying the canine microdystrophin cDNA in dys-
trophic dogs showed good expression of dystrophin, but a fast and 
strong immune response was observed against the capsid.9 Using 
the AAV8 vector, this immune response was delayed to 8 weeks, 
however, this delay will not insure a long-term microdystrophin 
expression if an immunosuppressive treatment is not admin-
istrated.10 Another team obtained good results using an AAV 
carrying the canine microdystrophin without immunosuppres-
sion in mdx mice.28 This team also observed canine microdystro-
phin expression for over 1 year with either direct intramuscular 
(AAV8) or regional limb or systemic intravenous (both AAV9) 
injection.29,30 If the AAV vectors are administered systemically 
by intravascular injection, they will spread throughout the body 
reaching other organs than skeletal muscles.31 In consequence, if 
there is an immune response against the viral capsid spread in the 
whole body, the risks of such a systemic immune response may be 
extremely severe. One study has shown weak toxicity following 
in vivo AAV systemic administration, but unfortunately the analy-
ses were only done during 3 days.32 With our ex vivo gene therapy 
approach, we avoid the problem of immune reactions against the 
viral capsid because the cells are genetically modified in vitro. 
The electrotransfer also avoid the immune response against the 
viral capsid because a naked plasmid is injected. Keeping in mind 
the considerations discussed above, it maybe be possible to avoid 
immunosuppression with these two methods. Toxicity, the need 
of immunosuppression and the spreading of the viral particles 
are also problems observed following direct in vivo injections of 
adenovirus.33,34 and for probably all viral vectors.35 There is, how-
ever, currently no evidence in the literature of these problems with 
the use of a lentivirus following ex vivo gene therapy. For these 
reasons, the ex vivo gene therapy may be a safer method than the 
direct injection of viral vectors to introduce a microdystrophin 
cDNA into dystrophic muscles and, eventually, into muscles of 
DMD patients.
In a clinical setup with our two methods, the dystrophin cDNA 
must be under the control of a muscle-specific promoter to avoid 
toxicity due to dystrophin expression in unfused MPCs or due to 
the dispersion of the plasmid to other organs. The absence of an 
antibiotic-resistance gene in the plasmids will be needed to avoid 
immune reactions against its product. However, since the random 
integration of the vector may induce tumorigenicity,35 samples of 
the cells transduced with lentivirus should be tested in vitro and 
in vivo, as previously done by our team for clinical trials of non-
dystrophic MPC transplantation.36
In conclusion, ex vivo gene therapy and plasmid electrotransfer 
must be improved to be used as potential treatments of  muscular 
dystrophies such as DMD.
MaterIal and Methods
Animals. Rag−/− mice were provided by Charles River (Willington, 
MA). Nondystrophic dogs were provided by La ferme aux toits oranges 
(Neuville, Quebec, Canada). All the experiments made on these animals 
were approved by the Animal Protection Committee of Laval University. 
The dystrophic dog came from a colony founded from one carrier female 
donated by J.N.K. The genotypes of the wild-type dogs and the dystro-
phic dog in pedigrees segregating golden retriever muscular dystrophy 
were confirmed by exon 7 specific genomic PCR followed by Sau96I 
digestion and analyzed by restriction fragments length polymorphism as 
described.37 The dystrophic dog was housed at the Muscular Dystrophy 
Research Center (AADM/UNAERP, Ribeirão Preto-SP, Brazil) according 
the guidelines set by the Institutional Laboratory Animal Care Committee 
of the University of Ribeirão Preto.
Cell culture. 293T cells were cultured in Dulbecco’s modified Eagle’s 
 medium-high glucose (Gibco, Burlington, Ontario, Canada) supple-
mented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and 
1% penicillin–streptomycin (Gibco). The hMPCs were obtained from a 
postmortem muscle sample of a normal 13-month-old male. These cells 
were proliferated in MCBD120 medium (Hyclone, Mississauga, Ontario, 
Canada) supplemented with 15% fetal bovine serum (Gibco), 1% pen-
icillin–streptomycin (Gibco), 10 µg/l of bFGF (Feldan, Saint-Laurent, 
Quebec, Canada), 0.4 mg/l of dexamethasone (Sigma, Oakville, Ontario, 
Canada), and 5 mg/l of insulin (Sigma). To obtain the activation of the 
MCK promoter, cells were cultured in differentiation medium [DMEM 
(Gibco) supplemented with 2% fetal bovine serum (Invitrogen)]. The 
dystrophic dog MPCs were isolated from a muscle biopsy of a 2-year-old 
dystrophic animal. Nondystrophic dog MPCs were obtained from muscle 
biopsies of a 3-month-old dog and a 3-year-old dog. Dystrophic and non-
dystrophic dog MPCs were cultured in the same medium as the hMPCs. 
All the cells were maintained at 37 °C under 5% CO2.
Lentiviral plasmid construction. Dog microdystrophin cDNA contained 
in an AAV vector28 was amplified with Turbo Pfu DNA polymerase with 
sense and reverse primers containing respectively at each ends BamH1 and 
Spe1 sites. Amplified product was purified from agarose gel and cloned 
by fusion (BD in Fusion; Clontech, Mountain View, CA) in BamH1/Spe1 
sites of lentiviral vector L6/V5 (Invitrogen) in which Xho1 site was elimi-
nated by cutting with Spe1/Xho1, followed by Klenow (GE Healthcare, 
Mississauga, Ontario, Canada) and ligated with T4 DNA ligase (NEB, 
Pickering, Ontario, Canada). Moreover, blasticidin contained in the lenti-
viral plasmid L6/V5 has been substituted by a puromycin resistance gene 
between the sites of Sma1/Kpn1 in the viral vector. The original cyto-
megalovirus promoter has been also substituted by the MCK promoter38 
making the final construct LeMCK.µDysV5 (Figure 1a). Constructs used 
to immortalize dog MPCs are described in reference.22 Both cDNAs cod-
ing for telomerase and Cdk4 were cloned each in L6/V5 in which the 
original resistant gene blasticidin was respectively substituted by puro-
mycin and hygromycin. Finally, pLeGFP construct is the result of cloning 
of eGFP cDNA39 cloned in L6/V5 and expressed with a cytomegalovirus 
promoter.
Virus production. Self-inactivating lentiviral vectors were produced with 
the third packaging system40 and the co-transfection method allowed 
their production as previously described.41 Briefly, psPAX2, pMD2G, 
and the vector plasmid were transfected in 293T cells using CaCl2 pre-
cipitation. The medium was removed 16 hours post-transfection and the 
supernatant was harvested at 12, 24, and 36 hours. Average titers were 
around 106 transduction units/ml. Cells were transduced with the len-
tivirus with a multiplicity of infection of 100 in the presence of 8 µg/ml 
of polybrene. The medium was removed after 12 hours. Cells transduced 
with a lentivirus coding for the puromycin resistance or the hygromy-
cin resistance gene were respectively selected during 2 days with the 
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puromycin (Clontech) at 2 µg/ml or during 1 week with the hygromycin 
(MultiCell Technologies, Woonsocket, RI) at 200 µg/ml, starting 2 days 
after the transduction.
Cell transplantation in mice. For human cell transplantation, Rag−/− 
mice were γ-ray irradiated (12Gy) at the leg level to inhibit the prolifera-
tion of the recipient satellite cells, a condition that favors the participation 
of grafted cells in recipient muscle regeneration.42 Two days before the 
graft, 1 µg of cardiotoxin (Sigma) was injected into the TAs to damage 
the muscle fibers inducing a process of muscle regeneration to induce the 
fusion of the transplanted cells.43 For the transplantations of nondystro-
phic and dystrophic dog MPCs, Rag−/− mice did not receive cardiotoxin 
nor irradiation.
Ten intramuscular injections were done for each MPC transplant-
ation in the TA muscle. A total of 106 cells (for hMPCs) or 5 × 105 cells (for 
dog MPCs) resuspended in 8 µl of Hank’s buffered salt solution (Gibco) 
in the TA were injected in each muscle. The grafted TAs were harvested 
1 month after transplantation and were snap frozen in liquid nitrogen. 
Serial 12-µm cryostat sections were obtained throughout the muscle.
Electrotransfer. Forty microgram of the pLeMCK.µDysV5 were injected 
percutaneously at a final volume of 40 µl of Tyrode’s buffer 1× (Sigma) in 
the mouse muscle. A single-longitudinal injection was made into the TA 
and the “Electrode Electrolyte” cream (Teca, Pleasantville, NY) was applied 
on the skin to favor the passage of the electric current between the two 
metal plaques. The generator used in this experiment delivers square wave 
pulses with the following parameters: 10 pulses of 200 V/cm, duration 
of 25 ms, and delay of 300 ms. The electrotransferred muscles were har-
vested 2 weeks after the experiment and were processed as the cell-grafted 
muscles.
For dogs, 200 µg of the pLeMCK.µDysV5 were injected at a final 
volume of 200 µl of Tyrode’s buffer 1× (Sigma) into the brachialis anterior. 
Two close injections of 100 µl were directly made into the muscle 
previously exposed by cutting the skin. Afterwards, two needles separated 
by 4 mm were implanted around the plasmid injection area and the 
electric pulses were applied. The electrical parameters for dogs were the 
same as for mice: 10 pulses of 200 V/cm, duration of 25 ms, and delay of 
300 ms. Suture points were placed in the muscle to distinguish the area 
of electrotransfer. The electrotransferred regions were biopsied 2 weeks 
later and the biopsies were prepared similar to that of the mouse muscles, 
except that the cryostat sections were 18-µm thick.
Western blot and histological analysis. Proteins from MPCs or myo-
tubes (3 days in differentiation medium) were extracted by a methanol– 
chloroform technique to perform western blots. Thirty microgram of 
proteins were loaded per well. The V5 tag was detected with a mouse 
anti-V5 antibody (1:5,000; Invitrogen). The Cdk4 was detected with a rab-
bit anti-Cdk4 antibody (1:500; eBioscience, San Diego, CA). The telom-
erase was detected with a rabbit anti-telomerase antibody (1:500; Acris, 
Herford, Germany) and a goat antidesmin antibody (1:200; Santa Cruz 
Biotechnology, Santa Cruz, CA) was used to detect desmin.
Hematoxylin–eosin staining was used for a morphological analysis 
of the grafted TAs. Immunohistochemistry to detect V5 was performed 
with a mouse anti-V5 antibody (1:200; Invitrogen) and dog dystrophin 
was detected with a mouse antidystrophin antibody MANDYS104 (1:8; 
CIND, Oswestry, UK), which reacts with dog but not mouse dystrophin. 
To detect the presence of CD8+ cells, a rat anti-CD8 antibody (1:80; AbD 
Serotec, Oxford, UK) was used. These primary antibodies were followed 
by incubation with a biotinylated anti-mouse or anti-rat antibody (1:300; 
Dako, Mississauga, Ontario, Canada) and with the Streptavidin-Cy3 
(1:300; Sigma). Afterwards, the sections were mounted in phosphate-
buffered saline-glycerol (1:1).
GFP and histological analyses were observed under fluorescence 
using an Axiophot microscope (Zeiss, Oberkochen, Germany).
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